Article
Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach.
Pharmacogenomics - 1 Aug 2010
Carotenuto Pietro, Roma Cristin, Rachiglio Anna Maria, Tatangelo Fabiana, Pinto Carmine, Ciardiello Fortunato, Nappi Oscar, Iaffaioli R Vincenzo, Botti Gerardo, Normanno Nicola
Abstract excerpt
AIMS: Patients with metastatic colorectal carcinoma (mCRC) carrying activating mutations of the KRAS gene do not benefit from treatment with anti-EGF receptor monoclonal antibodies. Therefore, KRAS mutation testing of mCRC patients is mandatory in the clinical setting to aid in the choice of appropriate therapy. MATERIALS & METHODS: We developed a cost-effective approach for the determination of KRAS mutations in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
